Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry.
Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry.
复制标题
非霍奇金淋巴瘤中细胞周期蛋白 D1 的表达。
DOI：
10.1093/ajcp/103.6.756
复制
发表时间：
1995
影响因子：
3.5
通讯作者：
Harris,NL
中科院分区：
文献类型：
--
作者：
Zukerberg,LR;Yang,WI;Arnold,A;Harris,NL
细胞周期蛋白D1/PRAD 1（bcl-1）是新近发现的一种原癌基因，在套细胞淋巴瘤和其他几种人类肿瘤中过表达。在之前的一项研究中，作者使用多克隆抗体和微波增强免疫组织化学染色方法在石蜡包埋的组织切片上证明了15例套细胞淋巴瘤中的15例和8例B慢性淋巴细胞白血病（B-CLL）中的1例中细胞周期蛋白D1的表达。在这项研究中，研究了107例额外的B和T细胞肿瘤，包括47例高度恶性淋巴瘤（33例弥漫性大B细胞型、9例Burkitt和Burkitt样、4例前体T淋巴母细胞淋巴瘤和1例成人T细胞淋巴瘤/白血病），另外38例低级别B细胞淋巴瘤（18例CLL，15例毛细胞白血病和5例套细胞淋巴瘤）和22例浆细胞瘤，使用相同的免疫组织化学染色技术检测细胞周期蛋白D1的表达。套细胞淋巴瘤均呈弥漫性核染色。没有其他CLL病例显示细胞周期蛋白D1表达。相反，15例毛细胞白血病中的1例和22例浆细胞瘤中的1例显示细胞周期蛋白D1染色。没有一个高级别的淋巴瘤表现出细胞周期蛋白D1蛋白的免疫染色的表达，包括三例大B细胞淋巴瘤，共表达CD 5。作者得出结论，细胞周期蛋白D1在套细胞淋巴瘤的所有病例中表达，并且仅在非常罕见的B-CLL、毛细胞白血病和浆细胞瘤/骨髓瘤的病例中表达。细胞周期蛋白D1似乎在高级别淋巴瘤中不起重要作用。此外，大多数CD 5阳性高级别B细胞淋巴瘤不表达细胞周期蛋白D1，并且不太可能来源于套细胞淋巴瘤或其他具有t（11;14）的淋巴瘤。
Cyclin D1/PRAD1 (bcl-1) is a recently discovered proto-oncogene that is overexpressed in mantle cell lymphomas and several other human tumors. In a previous study, the authors demonstrated expression of cyclin Dl in 15 of 15 cases of mantle cell lymphoma and 1 of 8 cases of B-chronic lymphocytic leukemia (B-CLL) using a polyclonal antibody and microwave enhanced immunohistochemical staining method on paraffin-embedded tissue sections. In this study, 107 additional B- and T-cell neoplasms were studied, including 47 cases of high grade lymphoma (33 diffuse large B-cell type, 9 Burkitt and Burkitt-like, 4 precursor T-lymphoblastic lymphoma, and 1 adult T-cell lymphoma/leukemia), 38 additional cases of low grade B-cell lymphoma (18 CLL, 15 hairy cell leukemia and 5 mantle cell lymphoma), and 22 plasmacytomas for expression of cyclin Dl using the same immunohistochemical staining technique. All cases of mantle cell lymphoma showed diffuse nuclear staining. No additional cases of CLL showed cyclin Dl expression. In contrast, 1 of 15 hairy cell leukemias and 1 of 22 plasmacytomas showed cyclin Dl staining. None of the high grade lymphomas demonstrated expression of cyclin Dl protein by immunostaining, including three cases of large B-cell lymphoma that coexpressed CD5. The authors conclude that cyclin Dl is expressed in all cases of mantle cell lymphoma, and only in very rare cases of B-CLL, hairy cell leukemia and plasmacytoma/myeloma. Cyclin Dl does not appear to play an important role in high grade lymphomas. In addition, most CD5 positive high grade B-cell lymphomas do not express cyclin Dl, and are not likely to be derived from mantle cell lymphoma or other lymphomas with t(11;14).